Diary of a decade – Ten years in Europe, the Middle East and Africa
July 13, 2015Medical Communications, Sales and Marketing Astellas, Ken Jones
It’s hard to imagine how much a company can change in a decade.When Astellas Pharma Europe was launched 10 years …
Roche posts positive mid-stage trial results for atezolizumab
July 13, 2015Research and Development Genentech, PD-L1, Phase II, Roche, anti-PD-L1, atezolizumab, clinical trial, immuno-oncology, personalised medicine
A cancer drug in development by Roche has performed well in a mid-phase clinical trial – prompting the Swiss firm …
Novo Nordisk pushes forward with new diabetes drug trial
July 13, 2015Research and Development GLP-1 agonist, Novo Nordisk, diabetes, phase III, semaglutide, type 2 diabetes
Novo Nordisk is taking the first steps towards adding another type 2 diabetes drug to its portfolio, after announcing positive …
NICE recommends Daiichi’s Lixiana for blood clots
July 13, 2015Sales and Marketing DVT, Daiichi, Daiichi Sankyo, Lixiana, NICE, NOACs, VTE, anticoagulant, blood clots, edoxaban, novel anticoagulant. PE
Daiichi Sankyo has won a speedy approval from NICE, after the NHS guidance body approved its newly-launched blood clotting drug …
Pharma dominates global M&A activity
July 10, 2015Sales and Marketing M&A, MA, acquisitions, mergers, takeovers
Mergers and acquisitions in the pharma, medical and biotech sectors have hit the highest levels in nearly 15 years, a …
NICE u-turns on Entyvio for Crohn’s disease
July 10, 2015Medical Communications, Sales and Marketing Crohn's, Crohn’s disease, Entyvio, Millenium, NICE, Takeda, funding
NICE has performed a u-turn and recommended drug treatment Entyvio for Crohn’s disease for routine NHS funding.In final draft guidance …
Daiichi Sankyo launches clotting drug Lixiana in UK
July 10, 2015Medical Communications, Sales and Marketing Daiichi Sankyo, Lixiana, NOAC, VTE, anticoagulant, atrial fibrillation, blood clots, edoxaban, novel anticoagulant, strokes, warfarin
Daiichi Sankyo’s Lixiana has become the latest pharma offering in the class of newer oral anticoagulants in the UK.Lixiana (edoxaban) …
Allergy expert Dr Hugh Sampson joing DBV Technologies
July 9, 2015Research and Development DBV Technologies, Viaskin
DBV Technologies has appointed Dr Hugh Sampson as its chief scientific officer. The French biotech company is developing the Viaskin peanut allergy treatment patch. Dr …
Praluent scores positive trial results in Japan
July 9, 2015Research and Development Japan, PCKS9, Regeneron, Sanofi, heart disease, high cholesterol, praluent
Praluent, the new heart drug from Sanofi and Regeneron, has met its primary endpoint in a Phase III study in …
Actavis contraceptives recalled after packaging errors
July 9, 2015Manufacturing and Production Actavis, FDA, manufacturing, packaging, product recall, production, recalls
Actavis is voluntarily recalling more than half a million boxes of contraceptive pills in the United States due to problems …
Horizon attempts a hostile $3bn Depomed takeover
July 9, 2015Manufacturing and Production, Research and Development, Sales and Marketing Depomed, M&A, MA, acquisitions, horizon, mergers, takeover
Dublin-based specialty pharmaceutical company Horizon has launched a bid to buy Depomed for $3 billion. Horizon, a biopharma company focussed …
Conservative announce NHS to receive a further £8 billion by 2020
July 9, 2015Budget, Chancellor, Chancellor of the exchequer, Conservatives, George Osborne, NHS, NHS funding, Tories, funding, government
The Conservative Government has confirmed the NHS will receive £10 billion in funding by 2020 in the Chancellor’s budget announcement.The …
Pegasus appoints two new members to its pharma team
July 8, 2015Medical Communications Pegasus
The health communications consultancy Pegasus is expanding its pharma and life sciences division, with the appointment of two new members …
Novartis wins US nod for new heart drug
July 8, 2015Research and Development, Sales and Marketing Entestro, FDA, LCZ696, Novartis, ejection fraction, heart failure, reduced ejection fraction, sacubitril
The FDA has given the green light to Novartis’ new heart failure drug, six weeks ahead of the scheduled date …
23andMe targets $150 million for drug development
July 8, 2015Research and Development 23andME, DNA, DNA testing, genetics, venture capital
The genetic testing firm 23andMe is seeking to raise $150 million in order to move into its own drug development …
European medicines group appoints Bayer’s Alex Moscho as new chair
July 7, 2015Manufacturing and Production, Research and Development, Sales and Marketing Alexander Moscho, EMG, European Medicines Group
Leading UK industry group the European Medicines Group (EMG) has elected Dr Alexander Moscho, the managing director of Bayer UK …
Pharma ‘paid US doctors $1.5 billion’ in 2014
July 7, 2015Medical Communications, Sales and Marketing Sunshine Act, US, pharma
Some of the largest European drugmakers paid US doctors and teaching hospitals $1.5 billion in 2014 to participate in promotional …
Teva ‘to increase Mylan bid to $43bn’
July 7, 2015Sales and Marketing M&A, MA, Mylan, Teva, generics
Israeli drugmaker Teva is considering whether to up its bid for US rival firm Mylan, with reports that it could …
Prescribing in England up 55% to £9bn over a decade
July 7, 2015Manufacturing and Production, Sales and Marketing NHS, NHSIC, drugs, health and social care information centre, net ingredient cost, prescribing
The number of drugs issued in England continues to soar, according to the latest NHS figures which show prescribing in …
Biogen to build billion-dollar plant in Switzerland
July 7, 2015Manufacturing and Production Alzherimer's disease, Biogen, Biogen IDEC, MS, Switzerland, manufacturing, multiple sclerosis
Biogen plans to open a $1 billion manufacturing facility in Switzerland, to help Europe deal with the future demand for …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
